| 6.32 -0.05 (-0.78%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.82  |
1-year : | 9.14 |
| Resists | First : | 6.69 |
Second : | 7.82 |
| Pivot price | 5.31 |
|||
| Supports | First : | 5 |
Second : | 3.96 |
| MAs | MA(5) : | 5.79 |
MA(20) : | 5.07 |
| MA(100) : | 5.15  |
MA(250) : | 6.79 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 85.9 |
D(3) : | 86.9 |
| RSI | RSI(14): 76 |
|||
| 52-week | High : | 11.42 | Low : | 3.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed above the upper band by 2.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 46.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.71 - 6.74 | 6.74 - 6.77 |
| Low: | 6.19 - 6.23 | 6.23 - 6.26 |
| Close: | 6.26 - 6.32 | 6.32 - 6.38 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Tue, 05 May 2026
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript - Insider Monkey
Tue, 05 May 2026
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Mon, 04 May 2026
Evolus Sees 2026 Rev $327M-$337M >EOLS - Moomoo
Mon, 04 May 2026
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally - ChartMill
Mon, 04 May 2026
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary - TradingView
Mon, 04 May 2026
Evolus (NASDAQ: EOLS) grows Q1 2026 sales but remains unprofitable - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 66 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 14.6 (%) |
| Held by Institutions | 76.2 (%) |
| Shares Short | 6,620 (K) |
| Shares Short P.Month | 7,620 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | -17.4 % |
| Operating Margin | -0.4 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 14.3 % |
| Gross Profit (p.s.) | 2.99 |
| Sales Per Share | 4.51 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -7.91 |
| PEG Ratio | 0 |
| Price to Book value | -18.06 |
| Price to Sales | 1.4 |
| Price to Cash Flow | -9.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|